Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

MicroRNAs as markers of progression in cervical cancer: a systematic review.

Pardini B, De Maria D, Francavilla A, Di Gaetano C, Ronco G, Naccarati A.

BMC Cancer. 2018 Jun 27;18(1):696. doi: 10.1186/s12885-018-4590-4.

2.

Author's reply to: Implementation and organization of cancer screening in France.

Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, Segnan N, Tomatis M, Soerjomataram I, Primic Žakelj M, Dillner J, Elfström KM, Lönnberg S, Sankaranaryanan R.

Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31629. [Epub ahead of print] No abstract available.

PMID:
29943811
3.

Impacts of human papillomavirus vaccination for different populations: A modeling study.

Baussano I, Lazzarato F, Ronco G, Franceschi S.

Int J Cancer. 2018 Sep 1;143(5):1086-1092. doi: 10.1002/ijc.31409. Epub 2018 Apr 16.

4.

Assessment of viral methylation levels for high risk HPV types by newly designed consensus primers PCR and pyrosequencing.

Gillio-Tos A, Fiano V, Grasso C, Trevisan M, Gori S, Mongia A, De Marco L, Ronco G; New Technologies for Cervical Cancer Screening (NTCC) Working Group.

PLoS One. 2018 Mar 26;13(3):e0194619. doi: 10.1371/journal.pone.0194619. eCollection 2018.

5.

Invitation strategies and coverage in the population-based cancer screening programmes in the European Union.

Vale DB, Anttila A, Ponti A, Senore C, Sankaranaryanan R, Ronco G, Segnan N, Tomatis M, Žakelj MP, Elfström KM, Lönnberg S, Dillner J, Basu P.

Eur J Cancer Prev. 2018 Mar 21. doi: 10.1097/CEJ.0000000000000426. [Epub ahead of print]

PMID:
29570103
6.

Author's reply to: Cancer screening policy in Hungary.

Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, Segnan N, Tomatis M, Soerjomataram I, Primic Žakelj M, Dillner J, Elfström KM, Lönnberg S, Sankaranarayanan R.

Int J Cancer. 2018 Aug 15;143(4):1005. doi: 10.1002/ijc.31371. Epub 2018 Mar 30. No abstract available.

PMID:
29524204
7.

Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more.

Del Mistro A, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, Rizzolo R, Frayle H, Trevisan M, Sani C, Burroni E, Giorgi Rossi P, Cuzick J, Ronco G; New Technologies for Cervical CancerWorking Group.

Int J Cancer. 2018 Jul 15;143(2):333-342. doi: 10.1002/ijc.31326. Epub 2018 Mar 9.

8.

Small non-coding RNA profiling in human biofluids and surrogate tissues from healthy individuals: description of the diverse and most represented species.

Ferrero G, Cordero F, Tarallo S, Arigoni M, Riccardo F, Gallo G, Ronco G, Allasia M, Kulkarni N, Matullo G, Vineis P, Calogero RA, Pardini B, Naccarati A.

Oncotarget. 2017 Dec 14;9(3):3097-3111. doi: 10.18632/oncotarget.23203. eCollection 2018 Jan 9.

9.

Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs.

Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, Carozzi F, Cubie H, Wentzensen N, Snijders P, Arbyn M, Monsonego J, Franceschi S.

Int J Cancer. 2018 Aug 15;143(4):735-745. doi: 10.1002/ijc.31261. Epub 2018 Feb 8. Review.

PMID:
29341110
10.

Causal system modelling of cervical cancer screening.

Ronco G, Baussano I.

Lancet Public Health. 2017 Feb;2(2):e61-e62. doi: 10.1016/S2468-2667(17)30013-0. Epub 2017 Feb 7. No abstract available.

11.

Cervical Cancer Screening: The Transformational Role of Routine Human Papillomavirus Testing.

Ronco G, Franceschi S.

Ann Intern Med. 2018 Jan 2;168(1):75-76. doi: 10.7326/M17-2872. Epub 2017 Nov 28. No abstract available.

PMID:
29181508
12.

Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.

Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, Segnan N, Tomatis M, Soerjomataram I, Primic Žakelj M, Dillner J, Elfström KM, Lönnberg S, Sankaranarayanan R.

Int J Cancer. 2018 Jan 1;142(1):44-56. doi: 10.1002/ijc.31043. Epub 2017 Oct 10. Erratum in: Int J Cancer. 2018 Jul 1;143(1):E1.

PMID:
28940326
13.

Role of HPV DNA testing in modern gynaecological practice.

Ronco G, Giorgi Rossi P.

Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:107-118. doi: 10.1016/j.bpobgyn.2017.08.002. Epub 2017 Aug 12. Review.

PMID:
28918099
14.

Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.

Baussano I, Lazzarato F, Ronco G, Lehtinen M, Dillner J, Franceschi S.

J Infect Dis. 2017 Aug 1;216(3):336-344. doi: 10.1093/infdis/jix299.

15.

Inequalities in cervical cancer screening utilisation and results: A comparison between Italian natives and immigrants from disadvantaged countries.

Gallo F, Caprioglio A, Castagno R, Ronco G, Segnan N, Giordano L.

Health Policy. 2017 Oct;121(10):1072-1078. doi: 10.1016/j.healthpol.2017.08.005. Epub 2017 Aug 10.

PMID:
28843514
16.

[Implementation of DNA-HPV primary screening in Italian cervical cancer screening programmes. Results of the MIDDIR Project].

Di Stefano F, Giorgi Rossi P, Carozzi F, Ronco G, Cacciani L, Vecchi S, Naldoni C, Segnan N; Gruppo di lavoro MIDDIR – HPV test in primary screening.

Epidemiol Prev. 2017 Mar-Apr;41(2):116-124. doi: 10.19191/EP17.2.P116.031. Italian.

PMID:
28627153
17.

Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.

Giorgi Rossi P, Bisanzi S, Allia E, Mongia A, Carozzi F, Gillio-Tos A, De Marco L, Ronco G, Gustinucci D, Del Mistro A, Frayle H, Iossa A, Fantacci G, Pompeo G, Cesarini E, Bulletti S, Passamonti B, Rizzi M, Penon MG, Barca A, Benevolo M.

J Clin Microbiol. 2017 Apr;55(4):1056-1065. doi: 10.1128/JCM.01794-16. Epub 2017 Jan 18.

18.

Interobserver reproducibility of cytologic p16INK4a /Ki-67 dual immunostaining in human papillomavirus-positive women.

Benevolo M, Allia E, Gustinucci D, Rollo F, Bulletti S, Cesarini E, Passamonti B, Giovagnoli MR, Carico E, Carozzi FM, Mongia A, Fantacci G, Confortini M, Rubino T, Fodero C, Prandi S, Marchi N, Farruggio A, Coccia A, Macrì L, Ghiringhello B, Ronco G, Bragantini E, Polla E, Maccallini V, Negri G, Giorgi Rossi P; New Technologies for Cervical Cancer Screening 2 (NTCC2) Working Group.

Cancer Cytopathol. 2017 Mar;125(3):212-220. doi: 10.1002/cncy.21800. Epub 2016 Dec 7.

19.

Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference.

Giorgi Rossi P, Carozzi F, Federici A, Ronco G, Zappa M, Franceschi S; Italian Screening in HPV vaccinated girls Consensus Conference group.

Prev Med. 2017 May;98:21-30. doi: 10.1016/j.ypmed.2016.11.020. Epub 2016 Nov 25.

20.

Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms.

Ronco G, Zappa M, Franceschi S, Tunesi S, Caprioglio A, Confortini M, Del Mistro A, Carozzi F, Segnan N, Zorzi M, Giorgi-Rossi P; Italian HPV Survey Working Group.

Eur J Cancer. 2016 Nov;68:148-155. doi: 10.1016/j.ejca.2016.09.008. Epub 2016 Oct 15.

21.

PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment.

Buonaiuto G, De Mori V, Braus A, Balini A, Berzi D, Carpinteri R, Forloni F, Meregalli G, Ronco GL, Bossi AC.

BMJ Open Diabetes Res Care. 2016 Jul 14;4(1):e000216. doi: 10.1136/bmjdrc-2016-000216. eCollection 2016.

22.

Sugammadex: The Right Option for the Efficiency of the Operating Room? A Methodology for Cost / Benefit Analysis in Comparison to the Routine Choice for Reversal.

Ronco GL.

Value Health. 2015 Nov;18(7):A732. doi: 10.1016/j.jval.2015.09.2800. Epub 2015 Oct 20. No abstract available.

23.

Prevention of Fragility Fractures in Osteoporotic Patients: Can the Secondary Therapy Help Contain Costs for Admissions? A Retrospective, Observational Case Control Study Based on Asl Pavia's Administrative Databases.

Ronco GL, Mirosa D, Silvia V, Carlo C.

Value Health. 2015 Nov;18(7):A656-7. doi: 10.1016/j.jval.2015.09.2373. Epub 2015 Oct 20. No abstract available.

24.

[Introduction of a centralised system (Service) for collecting clinical data in cancer screening programmes in Piedmont (Northern Italy): a pre-post assessment of a hub&spoke model].

Gallo F, Giubilato P, Larato C, Caprioglio A, Tomatis M, Calcagno M, Casella D, Di Leo A, Ponti A, Ronco G, Segnan N, Giordano L; Gruppo di lavoro Service.

Epidemiol Prev. 2015 Jul-Aug;39(4):243-50. Italian.

PMID:
26499237
25.

hr-HPV testing in the management of women with ASC-US+ and in the follow-up of women with cytological abnormalities and negative colposcopy. Recommendations of the Italian group for cervical cancer screening (GISCi).

Carozzi FM, Iossa A, Scalisi A, Sideri M, Andersson KL, Confortini M, Del Mistro A, Maina G, Ronco G, Raggi P, Schiboni ML, Zappa M, Giorgi Rossi P.

Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):84-90.

26.

A first survey of HPV-based screening in routine cervical cancer screening in Italy.

Ronco G, Giorgi Rossi P, Giubilato P, Del Mistro A, Zappa M, Carozzi F; HPV screening survey group.

Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):77-83.

27.

Extension of organized cervical cancer screening programmes in Italy and their process indicators, 2011-2012 activity.

Ronco G, Giubilato P, Carozzi F, Maia G, Giorgi Rossi P, Zappa M; Italian cervical cancer screening survey group.

Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):61-76.

28.

Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion.

Rossi PG, Ronco G, Dillner J, Elfström KM, Snijders PJ, Arbyn M, Berkhof J, Carozzi F, Del Mistro A, De Sanjosè S, Bosch X, Petry KU, Poljak M, Naldoni C, Meijer CJ; Comparing Health Services Interventions for the Prevention of HPV-Related Cancer Consortium; New Technologies for Cervical Cancer Group.

Cancer Cytopathol. 2016 Jan;124(1):66-7. doi: 10.1002/cncy.21622. Epub 2015 Sep 10. No abstract available.

29.

HPV-FASTER: broadening the scope for prevention of HPV-related cancer.

Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M, Petry KU, Poljak M, Kjaer SK, Meijer CJ, Garland SM, Salmerón J, Castellsagué X, Bruni L, de Sanjosé S, Cuzick J.

Nat Rev Clin Oncol. 2016 Feb;13(2):119-32. doi: 10.1038/nrclinonc.2015.146. Epub 2015 Sep 1. Review.

PMID:
26323382
30.

Changes in cervical cancer incidence following the introduction of organized screening in Italy.

Serraino D, Gini A, Taborelli M, Ronco G, Giorgi-Rossi P, Zappa M, Crocetti E, Franzo A, Falcini F, Visioli CB, Stracci F, Zorzi M, Federico M, Michiara M, Fusco M, Ferretti S, Pannozzo F, Tisano F, Zanetti R, Zucchetto A; Members of ‘IMPATTO-CERVICE’ working group; Members of 'IMPATTO-CERVICE' working group.

Prev Med. 2015 Jun;75:56-63. doi: 10.1016/j.ypmed.2015.01.034. Epub 2015 Mar 27.

PMID:
25818232
31.

Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial.

Bergeron C, Giorgi-Rossi P, Cas F, Schiboni ML, Ghiringhello B, Dalla Palma P, Minucci D, Rosso S, Zorzi M, Naldoni C, Segnan N, Confortini M, Ronco G.

J Natl Cancer Inst. 2015 Jan 7;107(2). pii: dju423. doi: 10.1093/jnci/dju423. Print 2015 Feb.

32.

Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology.

Allia E, Ronco G, Coccia A, Luparia P, Macrì L, Fiorito C, Maletta F, Deambrogio C, Tunesi S, De Marco L, Gillio-Tos A, Sapino A, Ghiringhello B.

Cancer Cytopathol. 2015 Apr;123(4):212-8. doi: 10.1002/cncy.21511. Epub 2014 Dec 22.

33.

The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials.

Veldhuijzen NJ, Berkhof J, Gillio-Tos A, De Marco L, Carozzi F, Del Mistro A, Snijders PJ, Meijer CJ, Ronco G.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):111-8. doi: 10.1158/1055-9965.EPI-14-0628. Epub 2014 Oct 9.

34.

Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.

Carozzi F, De Marco L, Gillio-Tos A, Del Mistro A, Girlando S, Baboci L, Trevisan M, Burroni E, Grasso S, Giorgi Rossi P, Ronco G; NTCC Working Group.

J Clin Virol. 2014 Jul;60(3):257-63. doi: 10.1016/j.jcv.2014.04.009. Epub 2014 Apr 18.

PMID:
24815381
35.

The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments.

Bergeron C, Ronco G, Reuschenbach M, Wentzensen N, Arbyn M, Stoler M, von Knebel Doeberitz M.

Int J Cancer. 2015 Jun 15;136(12):2741-51. doi: 10.1002/ijc.28900. Epub 2014 May 12. Review.

36.

HPV-based screening for prevention of invasive cervical cancer - Authors' reply.

Ronco G, Meijer CJ, Segnan N, Kitchener H, Giorgi-Rossi P, Peto J, Dillner J.

Lancet. 2014 Apr 12;383(9925):1295. doi: 10.1016/S0140-6736(14)60645-0. No abstract available.

PMID:
24725577
37.

The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening Programs.

Giorgi Rossi P, Baldacchini F, Ronco G.

Front Oncol. 2014 Feb 10;4:20. doi: 10.3389/fonc.2014.00020. eCollection 2014. Review.

38.

Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model.

Baussano I, Dillner J, Lazzarato F, Ronco G, Franceschi S.

Infect Agent Cancer. 2014 Jan 20;9(1):4. doi: 10.1186/1750-9378-9-4.

39.

Type-specific human papillomavirus biological features: validated model-based estimates.

Baussano I, Elfström KM, Lazzarato F, Gillio-Tos A, De Marco L, Carozzi F, Del Mistro A, Dillner J, Franceschi S, Ronco G.

PLoS One. 2013 Nov 29;8(11):e81171. doi: 10.1371/journal.pone.0081171. eCollection 2013.

40.

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.

Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ; International HPV screening working group.

Lancet. 2014 Feb 8;383(9916):524-32. doi: 10.1016/S0140-6736(13)62218-7. Epub 2013 Nov 3. Erratum in: Lancet. 2015 Oct 10;386(10002):1446.

PMID:
24192252
41.

Re: lead time and down-staging in the survival of cervical cancer cases detected by screening.

Zucchetto A, Ronco G, Giorgi Rossi P, Zappa M, Serraino D; IMPATTO CERVICE Working Group.

Prev Med. 2013 Oct;57(4):404-5. doi: 10.1016/j.ypmed.2013.08.006. Epub 2013 Aug 14. No abstract available.

PMID:
23954188
42.

Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.

Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, Frayle-Salamanca H, Giorgi Rossi P, Pierotti P, Ronco G; New Technologies for Cervical Cancer Screening Working Group.

J Clin Microbiol. 2013 Sep;51(9):2901-7. doi: 10.1128/JCM.01047-13. Epub 2013 Jun 26.

43.

Screening patterns within organized programs and survival of Italian women with invasive cervical cancer.

Zucchetto A, Ronco G, Giorgi Rossi P, Zappa M, Ferretti S, Franzo A, Falcini F, Visioli CB, Zanetti R, Biavati P, La Rosa F, Baracco S, Federico M, Campari C, De Togni A, Piffer S, Pannozzo F, Fusco M, Michiara M, Castaing M, Seghini P, Tisano F, Serraino D; IMPATTO CERVICE Working Group.

Prev Med. 2013 Sep;57(3):220-6. doi: 10.1016/j.ypmed.2013.05.018. Epub 2013 Jun 1.

PMID:
23732239
44.

Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial.

Baussano I, Franceschi S, Gillio-Tos A, Carozzi F, Confortini M, Dalla Palma P, De Lillo M, Del Mistro A, De Marco L, Naldoni C, Pierotti P, Schincaglia P, Segnan N, Zorzi M, Giorgi-Rossi P, Ronco G.

BMC Infect Dis. 2013 May 24;13:238. doi: 10.1186/1471-2334-13-238.

45.

Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.

Baussano I, Lazzarato F, Ronco G, Dillner J, Franceschi S.

Int J Cancer. 2013 Oct 15;133(8):1876-81. doi: 10.1002/ijc.28197. Epub 2013 May 15.

46.

A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years.

Giambi C, Donati S, Carozzi F, Salmaso S, Declich S, Atti ML, Ronco G, Alibrandi MP, Brezzi S, Collina N, Franchi D, Lattanzi A, Minna MC, Nannini R, Barretta E, Burroni E, Gillio-Tos A, Macallini V, Pierotti P, Bella A.

BMC Infect Dis. 2013 Feb 7;13:74. doi: 10.1186/1471-2334-13-74.

47.

[Cervical cancer screening in Italy: quality of colposcopy and treatment. 2010 activity].

Volante R, Giubilato P, Ronco G.

Epidemiol Prev. 2012 Nov-Dec;36(6 Suppl 1):78-86. Italian.

48.

[Extension of organised cervical cancer screening programmes in Italy and their process indicators, 2010 activity].

Ronco G, Giubilato P, Naldoni C, Zorzi M, Anghinoni E, Scalisi A, Dalla Palma P, Zanier L, Barca A, Angeloni C, Gaimo MD, Maglietta R, Mancini E, Pizzuti R, Iossa A, Segnan N, Zappa M.

Epidemiol Prev. 2012 Nov-Dec;36(6 Suppl 1):39-54. Italian.

49.

Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.

Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, Girlando S, Rosso S, Naldoni C, Dalla Palma P, Zorzi M, Giorgi-Rossi P, Segnan N, Cuzick J, Ronco G; NTCC working group.

Lancet Oncol. 2013 Feb;14(2):168-76. doi: 10.1016/S1470-2045(12)70529-6. Epub 2012 Dec 21.

PMID:
23261355
50.

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.

Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Review. Erratum in: Vaccine. 2013 Dec 16;31(52):6266.

PMID:
23199969

Supplemental Content

Support Center